You just read:

Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016

News provided by

Viking Therapeutics, Inc

Sep 01, 2016, 07:30 ET